|81.22||+0.2700||+0.33%||Vol 541.69K||1Y Perf 65.86%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||85.73||Analyst Rating||Moderate Buy 1.73|
|Potential %||5.55||Finscreener Ranking||★★★ 49.50|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.02|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 63.05|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||91.69||Earnings Rating||Buy|
|Market Cap||8.19B||Earnings Date||27th Oct 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Oct 2021|
|Estimated EPS Next Report||0.45|
|EPS Growth Next 5 Years %||10.60|
|Avg. Weekly Volume||415.69K|
|Avg. Monthly Volume||498.20K|
|Avg. Quarterly Volume||460.19K|
Globus Medical Inc. Class A (NYSE: GMED) stock closed at 81.22 per share at the end of the most recent trading day (a 0.33% change compared to the prior day closing price) with a volume of 542.02K shares and market capitalization of 8.19B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 2200 people. Globus Medical Inc. Class A CEO is David M. Demski.
The one-year performance of Globus Medical Inc. Class A stock is 65.86%, while year-to-date (YTD) performance is 24.53%. GMED stock has a five-year performance of 259.7%. Its 52-week range is between 48 and 84.23, which gives GMED stock a 52-week price range ratio of 91.69%
Globus Medical Inc. Class A currently has a PE ratio of 44.80, a price-to-book (PB) ratio of 4.97, a price-to-sale (PS) ratio of 8.61, a price to cashflow ratio of 32.10, a PEG ratio of 2.32, a ROA of 10.90%, a ROC of 12.37% and a ROE of 12.07%. The company’s profit margin is 20.09%, its EBITDA margin is 31.90%, and its revenue ttm is $927.90 Million , which makes it $9.20 revenue per share.
Of the last four earnings reports from Globus Medical Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.45 for the next earnings report. Globus Medical Inc. Class A’s next earnings report date is 27th Oct 2021.
The consensus rating of Wall Street analysts for Globus Medical Inc. Class A is Moderate Buy (1.73), with a target price of $85.73, which is +5.55% compared to the current price. The earnings rating for Globus Medical Inc. Class A stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Globus Medical Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Globus Medical Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 6.20, ATR14 : 1.72, CCI20 : -29.52, Chaikin Money Flow : 0.04, MACD : 0.06, Money Flow Index : 38.64, ROC : -3.38, RSI : 52.80, STOCH (14,3) : 48.14, STOCH RSI : 0.94, UO : 44.60, Williams %R : -51.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Globus Medical Inc. Class A in the last 12-months were: Ann D. Rhoads (Sold 0 shares of value $-163 993 ), Daniel T. Scavilla (Sold 0 shares of value $-1 313 500 ), Daniel T. Scavilla (Sold 100 000 shares of value $7 841 224 ), David D. Davidar (Sold 42 000 shares of value $2 520 000 ), David M. Demski (Sold 0 shares of value $-10 240 445 ), David M. Demski (Sold 482 597 shares of value $32 931 951 ), James R. Tobin (Sold 0 shares of value $-1 094 250 ), James R. Tobin (Sold 25 000 shares of value $1 799 000 ), Keith W. Pfeil (Sold 0 shares of value $-1 839 439 ), Keith W. Pfeil (Sold 35 833 shares of value $2 701 114 ), Kelly G. Huller (Sold 0 shares of value $-22 560 ), Kelly G. Huller (Sold 2 000 shares of value $132 300 ), Lemaitre Dan (Sold 0 shares of value $-173 532 ), Lemaitre Dan (Sold 15 384 shares of value $961 039 )
Thu, 05 Aug 2021 16:31 GMT Globus Medical (GMED) Gets a Hold Rating from Morgan Stanley- TipRanks. All rights reserved.
Thu, 05 Aug 2021 16:31 GMT Citigroup Believes Globus Medical (GMED) Still Has Room to Grow- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.